GMPPA defects cause a neuromuscular disorder with α-dystroglycan hyperglycosylation
Authors:
- Patricia FranzkaPFPatricia Franzka
- Henriette HenzeHHHenriette Henze
- M. Juliane JungMJM. Juliane Jung
- Sonnhild MittagSMSonnhild Mittag
- Karina BiskupKBKarina Biskup
- Lutz LiebmannLLLutz Liebmann
- Takfarinas KentacheTKTakfarinas Kentache
- José MoralesJMJosé Morales
- Braulio MartínezBMBraulio Martínez
- Istvan KatonaIKIstvan Katona
- Tanja HerrmannTHTanja Herrmann
- 3 May 2021
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (9)
Abstract
GDP-mannose-pyrophosphorylase-B (GMPPB) facilitates the generation of GDP-mannose, a sugar donor required for glycosylation. GMPPB defects cause muscle disease due to hypoglycosylation of α-dystroglycan (α-DG). Alpha-DG is part of a protein complex, which links the extracellular matrix with the cytoskeleton, thus stabilizing myofibers. Mutations of the catalytically inactive homolog GMPPA cause alacrima, achalasia, and mental retardation syndrome (AAMR syndrome), which also involves muscle weakness. Here, we showed that Gmppa-KO mice recapitulated cognitive and motor deficits. As structural correlates, we found cortical layering defects, progressive neuron loss, and myopathic alterations. Increased GDP-mannose levels in skeletal muscle and in vitro assays identified GMPPA as an allosteric feedback inhibitor of GMPPB. Thus, its disruption enhanced mannose incorporation into glycoproteins, including α-DG in mice and humans. This increased α-DG turnover and thereby lowered α-DG abundance. In mice, dietary mannose restriction beginning after weaning corrected α-DG hyperglycosylation and abundance, normalized skeletal muscle morphology, and prevented neuron degeneration and the development of motor deficits. Cortical layering and cognitive performance, however, were not improved. We thus identified GMPPA defects as the first congenital disorder of glycosylation characterized by α-DG hyperglycosylation, to our knowledge, and we have unraveled underlying disease mechanisms and identified potential dietary treatment options.Keywords
Funding Information
- DFG (GRK 2155 ProMoAge)
- DFG (MA-3975/2-1)
- eu (EUROGLYCAN-omics network,E-Rare-3 Joint Transnational Call)
This publication has 46 references indexed in Scilit:
- A spastic paraplegia mouse model reveals REEP1-dependent ER shapingJournal of Clinical Investigation, 2013
- Serum Glycome Profiling: A Biomarker for Diagnosis of Ovarian CancerJournal of Proteome Research, 2013
- Measuring the Strength of MiceJournal of Visualized Experiments, 2013
- Congenital disorders of glycosylation (CDG): it's (nearly) all in it!Journal of Inherited Metabolic Disease, 2011
- Mannose Efflux from the CellsJournal of Biological Chemistry, 2011
- Transgenic Overexpression of LARGE Induces α-Dystroglycan Hyperglycosylation in Skeletal and Cardiac MusclePLOS ONE, 2010
- O -Mannosyl Phosphorylation of Alpha-Dystroglycan Is Required for Laminin BindingScience, 2010
- Acre-transgenic mouse strain for the ubiquitous deletion ofloxP-flanked gene segments including deletion in germ cellsNucleic Acids Research, 1995
- Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrixNature, 1992
- Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning.Behavioral Neuroscience, 1992